IL310187A - Antibody preparations against B7-H3 and their use - Google Patents

Antibody preparations against B7-H3 and their use

Info

Publication number
IL310187A
IL310187A IL310187A IL31018724A IL310187A IL 310187 A IL310187 A IL 310187A IL 310187 A IL310187 A IL 310187A IL 31018724 A IL31018724 A IL 31018724A IL 310187 A IL310187 A IL 310187A
Authority
IL
Israel
Prior art keywords
cancer
pharmaceutical composition
enoblituzumab
composition
container
Prior art date
Application number
IL310187A
Other languages
English (en)
Hebrew (he)
Inventor
Zhou Yan
Sampathkumar Krishnan
James BURKE Stephen
Wang Xiaoyan
Original Assignee
Macrogenics Inc
Zhou Yan
Sampathkumar Krishnan
James BURKE Stephen
Wang Xiaoyan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc, Zhou Yan, Sampathkumar Krishnan, James BURKE Stephen, Wang Xiaoyan filed Critical Macrogenics Inc
Publication of IL310187A publication Critical patent/IL310187A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL310187A 2021-07-16 2022-07-06 Antibody preparations against B7-H3 and their use IL310187A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163222750P 2021-07-16 2021-07-16
PCT/US2022/073462 WO2023288173A1 (en) 2021-07-16 2022-07-06 Pharmaceutical compositions of a b7-h3 antibody and use of the same

Publications (1)

Publication Number Publication Date
IL310187A true IL310187A (en) 2024-03-01

Family

ID=84920541

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310187A IL310187A (en) 2021-07-16 2022-07-06 Antibody preparations against B7-H3 and their use

Country Status (11)

Country Link
US (1) US20240336687A1 (cg-RX-API-DMAC10.html)
EP (1) EP4370155A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024526773A (cg-RX-API-DMAC10.html)
KR (1) KR20240038005A (cg-RX-API-DMAC10.html)
CN (1) CN117715657A (cg-RX-API-DMAC10.html)
AU (1) AU2022310668A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224118A1 (cg-RX-API-DMAC10.html)
IL (1) IL310187A (cg-RX-API-DMAC10.html)
MX (1) MX2024000690A (cg-RX-API-DMAC10.html)
TW (1) TW202310874A (cg-RX-API-DMAC10.html)
WO (1) WO2023288173A1 (cg-RX-API-DMAC10.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112012033457A2 (pt) * 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
EP3714901A4 (en) * 2017-12-22 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. ANTI-LAG-3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20230041197A1 (en) * 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
JP7641908B2 (ja) * 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Il-5に対する抗体を含有する医薬組成物及びその使用
KR20220119694A (ko) * 2019-12-23 2022-08-30 마크로제닉스, 인크. 암 치료를 위한 요법
CN115103691B (zh) * 2020-03-25 2025-01-24 苏州盛迪亚生物医药有限公司 一种含抗体药物偶联物的药物组合物及其用途

Also Published As

Publication number Publication date
EP4370155A4 (en) 2025-06-11
WO2023288173A1 (en) 2023-01-19
AU2022310668A1 (en) 2024-01-18
CA3224118A1 (en) 2023-01-19
MX2024000690A (es) 2024-02-07
KR20240038005A (ko) 2024-03-22
US20240336687A1 (en) 2024-10-10
CN117715657A (zh) 2024-03-15
EP4370155A1 (en) 2024-05-22
TW202310874A (zh) 2023-03-16
JP2024526773A (ja) 2024-07-19

Similar Documents

Publication Publication Date Title
US20150239970A1 (en) Stable, Low Viscosity Antibody Formulation
IL275038B2 (en) Formulation for anti-antibody alpha 4 in cell 7
ES2668900T3 (es) Formulaciones estabilizadas que contienen anticuerpos anti-Dll4
JP2023540025A (ja) 二重特異性egfr/c-met抗体を含む安定な製剤
Maeder et al. Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration
AU2022310668A1 (en) Pharmaceutical compositions of a b7-h3 antibody and use of the same
US12364756B2 (en) Pharmaceutical compositions of a PD-1 antibody and use of the same
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
US20230053747A1 (en) Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
HK40112469A (en) Pharmaceutical compositions of a pd-1 antibody and use of the same
EA050933B1 (ru) Фармацевтические композиции антитела к pd-1 и применение указанной композиции
CN116916952A (zh) HER2/neu抗体的药物组合物及其用途
HK40102521A (en) Pharmaceutical compositions of a her2/neu antibody and use of the same
WO2025140467A1 (zh) 稳定的高浓度抗pd-1抗体药物制剂
HK40115478A (en) Aqueous formulations of an anti-cd22 antibody and uses thereof
ES2702246T3 (es) Formulaciones de agente de unión IgG4 estables
KR20230026407A (ko) 액티빈 a 항체 제형 및 이의 사용 방법
TR2025000822T2 (tr) Anti̇-cd20 anti̇kor farmasöti̇k bi̇leşi̇mi̇ ve bunun kullanimi
HK40059591A (en) Preparations containing anti-cd47 antibody, and preparation method and use therefor